-+ 0.00%
-+ 0.00%
-+ 0.00%

Keybanc Maintains Overweight on ResMed, Raises Price Target to $277

Benzinga·10/30/2026 12:45:37
Listen to the news
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.